Replies to post #5459 on REVE Technologies, Inc (BSSP)

[PENNIEStoSTACKS]

BSSP - The initial deployment for sales of the specific IPF for Cancer indication product and treatment programs to Mexico are now in process with four hospitals positioned and in process of licensing requirements which have been submitted. Canteck is positioned to oversee the development, manufacturing and commercialization processes for our lead product to be the Irreversible Pepsin Fraction (IPF) specific to the Cancer indication, with options for other indications.

"Our transition to the corporate platform for development and deployment of targeted therapeutic immunotherapeutic technology represents an important event in our transition and growth," said Dennis Alexander, CEO of the Company. "Further, the Company welcomes our current and future development with Canteck Pharma, Inc., and working together with our new Board of Directors and Management including Mr. and Mrs. Zhabilov, as the Company looks forward to bringing these novel technological advancements to the forefront initially to Mexico to assist treatment and solutions for specific Cancer treatment and to become available in a cost effective manner to assist the severity of medical needs going unmet."

"The licensing agreement with Reve Technologies, Inc. is very much an important milestone in our goal to develop and commercialize our immune-oncology based IPF treatment as a new therapy for difficult-to-treat tumor indications on a scalable international level initially in Mexico." Said Mr. Harry Zhabilov, Jr. BSc, McS and newly appointed Chief Sciencist of the Company. "We are delighted to have a committed partner and management team and with our missions aligned and look forward to working together to obtain approvals for our IPF Irreversible Pepsin Fraction specific to the Cancer indication, and to bring these much-needed therapeutic options as soon as possible for delivery and availability to Mexico.

Sounds like a lot of UPDATES will be coming fairly quickly
http://marketersmedia.com/reve-acquires-exclusive-license-for-cantecks-ipf-irreversable-pepsin-fraction-specific-to-cancer-indication-only-for-mexico/112197

[kommisar7]

This is a 20 million dollar company when the hospital news hit imo, and that puts the stock price at .016, imo.

may I ask how you come to this bill ....?
20 / 1.2 billion = $ 0.016
why 20 million revenue
why 1.2 billion OS
I do not know the OS

[stervc]

robertking, to justify your BSSP valuation…

Before I justify your BSSP valuation, I must say first that I believe that you were initially correct with assessing the Stage 3 clinical trials in Europe to be for the therapy to treat HIV at a hospital in Bulgaria. It is known that it was a Bulgarian Hospital that gave Dr. Zhabilov $2 million USD so the Irreversible Pepsin Fraction (IPF) therapy for HIV could get approved in Europe (EU). Although BSSP/Canteck Pharma, Inc. did not mention such within their recent PR and only mentioned that they have current and planned operations in Mexico through the exclusive Sub Licensing Agreement for IPF specific to the Cancer, there is some serious research that confirms your initial research on the matter within the slideshow below:
http://www.cantechpharma.com/wp-content/uploads/2016/02/Cantech-IPF.pdf


Now let’s justify your BSSP valuation of which I believe is very fair and conservative. I too will try to be as conservative as possible too in delivering these thoughts.

Within the recent 8-K that BSSP filed with the SEC, they stated that the Authorized Shares (AS) was 5,000,000,000 Shares:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/0001594062-16-000450-index.htm
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/form8k.htm

So, as a worst case scenario, let’s presume that the Outstanding Shares (OS) for BSSP is maxed out to be the 5,000,000,000 shares.

Although I think the potential is far greater, let’s now presume that BSSP is a $20,000,000 company as you have conservatively stated.

I think everyone here can agree that BSSP/Canteck Pharma, Inc. would exist to trade within the Healthcare Sector and within the Industry titled Drug Manufacturers – Other. Within the link below, you will see that the current Price to Earnings (P/E) Ratio is 27.90 and the current Net Profit Margin is 18.5%:

https://biz.yahoo.com/p/5conameu.html


Now that we have some Key Fundamental Variables, we can assess a Fundamental Valuation for where BSSP could logically trade upon the consummation of BSSP completing the One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations in Mexico:
http://finance.yahoo.com/news/reve-acquires-exclusive-license-cantecks-133000687.html

Key Fundamental Variables
** Net Income = $20,000,000 Revenues x .185 Net Profit Margin = $3,700,000 Net Income
** OS = 5,000,000,000 Shares
** P/E Ratio for Technology Sector = 27.90
** Net Income ÷ OS = EPS
** EPS x P/E Ratio = Per Share Valuation

$3,700,000 Net Income ÷ 5,000,000,000 (OS) = .00074 EPS

.00074 EPS x 27.90 P/E Ratio = .0206 Per Share Valuation

From the thoughts above, I hope you can see why the .016 per share valuation that you have considered is fair for BSSP if they close this deal. I also hope one would see that the above .0206 Per Share Valuation for BSSP that was derived through logical deduction from the given variables above is also fair to consider.

I think too it is important for one to use the Substitution Property for any of the variables that would change as more details are ”officially” released from the company through their PRs and their SEC filings. So, as a worst case scenario from the variables above, BSSP is significantly undervalued here at these levels if this deal with Canteck Pharma, Inc. closes. This is why I believe, in my opinion, it’s just a matter of time before the rest of the market or enough of the market realizes such.

v/r
Sterling